Urashima M, Chauhan D, Uchiyama H, Freeman G J, Anderson K C
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Blood. 1995 Apr 1;85(7):1903-12.
Previous studies have suggested that interleukin-6 (IL-6) may mediate growth of multiple myeloma (MM) in either an autocrine or paracrine growth mechanism. However, those molecules which can trigger IL-6 secretion either by tumor cells or non-MM marrow cells are not well characterized. In the present study, we have examined the expression and functional significance of CD40 on MM and plasma cell leukemia (PCL) cells and derived cell lines, as well as long-term bone marrow stromal cells (BMSCs) and derived cell lines. CD40 was expressed on the majority of MM cells (> 90%) and BMSCs (> 70%). Triggering via CD40 using NIH3T3 CD40 ligand transfectant (CD40LT) cells increased (> 30%) cell surface CD80, CD18, CD11a, CD11b, and CD11c expression on MM cell lines. Culture with either fresh or paraformaldehyde fixed NIH3T3 CD40LT cells upregulates IL-6 secretion in MM cells and MM-derived cell lines, as well as normal and MM bone marrow mononuclear cells (BMMCs), BMSCs, and BMSC lines; this effect can be specifically blocked by anti-CD40 monoclonal antibody (MoAb). BMMCs and BMSCs from patients with MM secreted significantly more IL-6 than those from healthy donors (n = 3, P < .001); moreover, after stimulation using CD40L, IL-6 secretion was fourfold greater (n = 3, P < .001) from MM BMMCs and BMSCs than from normal BMMCs and BMSCs. Myeloma (CD38+CD45RA-) cells and non-MM (CD38+CD45RA+, CD38-CD45RA+, and CD38-CD45RA-) BMMCs were separated by dual fluorescence cell sorting. The latter secreted fourfold more IL-6 than the former (n = 2, P < .001). Increased IL-6 secretion (up to 28-fold) and proliferation (Stimulation index 10) by CD38+CD45RA-MM cells was triggered by culture with NIH3T3 CD40LT cells. Finally, anti-CD40MoAb partially (30%) blocked tumor cell to BMSC adhesion-induced IL-6 secretion. These studies support the view that CD40L may trigger IL-6 secretion by both MM cells and BMSCs and that IL-6-mediated autocrine and paracrine growth mechanisms may be possible in MM.
以往研究提示,白细胞介素-6(IL-6)可能通过自分泌或旁分泌生长机制介导多发性骨髓瘤(MM)的生长。然而,那些可触发肿瘤细胞或非MM骨髓细胞分泌IL-6的分子尚未得到充分表征。在本研究中,我们检测了CD40在MM、浆细胞白血病(PCL)细胞及其衍生细胞系,以及长期骨髓基质细胞(BMSC)及其衍生细胞系中的表达及功能意义。大多数MM细胞(>90%)和BMSC(>70%)表达CD40。使用NIH3T3 CD40配体转染细胞(CD40LT)通过CD40触发可增加(>30%)MM细胞系细胞表面CD80、CD18、CD11a、CD11b和CD11c的表达。与新鲜或经多聚甲醛固定的NIH3T3 CD40LT细胞共培养可上调MM细胞、MM衍生细胞系、正常和MM骨髓单个核细胞(BMMC)、BMSC及BMSC系中IL-6的分泌;这种效应可被抗CD40单克隆抗体(MoAb)特异性阻断。MM患者的BMMC和BMSC分泌的IL-6明显多于健康供者(n = 3,P <.001);此外,用CD-40L刺激后,MM的BMMC和BMSC分泌的IL-6比正常BMMC和BMSC多四倍(n = 3,P <.001)。通过双荧光细胞分选分离骨髓瘤(CD38+CD45RA-)细胞和非MM(CD38+CD45RA+³、CD38-CD45RA+和CD38-CD45RA-)BMMC。后者分泌的IL-6比前者多四倍(n = 2,P <.001)。与NIH3T3 CD40LT细胞共培养可触发CD38+CD45RA-MM细胞IL-6分泌增加(高达28倍)和增殖(刺激指数10)。最后,抗CD40MoAb可部分(30%)阻断肿瘤细胞与BMSC黏附诱导的IL-6分泌。这些研究支持以下观点,即CD40L可能触发MM细胞和BMSC分泌IL-6,且IL-6介导的自分泌和旁分泌生长机制在MM中可能存在。